Paris, France — 20 March 2023 — Genèse Labs has been re-established as Genèse Labs France, shifting its business model from the distribution of aesthetic products to in-house product development and global brand ownership.

Under EU cosmetics law, every product placed on the European market must have a designated Responsible Person established within the EU, who bears legal responsibility for product safety and regulatory compliance. By operating as a French entity, Genèse Labs became able to serve as the Responsible Person for its own products, file regulatory notifications directly, and maintain product documentation under its own control. For a company planning to launch multiple lines across several categories, this in-house capability meaningfully reduced both cost and time to market.

The re-establishment came with a reallocation of resources toward formulation development, clinical validation and intellectual-property protection. Where the previous structure had prioritised commercial reach, the new organisation prioritised depth of product pipeline — restructured around regulatory affairs, product development and international marketing. The company’s goal of bringing an in-house product to market within the same year was achieved with the launch of RG60®.

The French entity also provided an institutional foundation for markets beyond Europe. Regulatory authorities and distribution partners in Asia, the Middle East and Latin America read EU-compliant documentation as an indicator of product quality and manufacturing discipline. A product developed in France and validated to European standards carries a credibility that accelerates entry elsewhere — an advantage that proved central to the expansion that followed, including KFDA registration in Korea.

Genèse Labs is a Paris-founded aesthetic company dedicated to science-based, regulatory-led product development across the fast-growing fields of body contouring, collagen biostimulation, and regenerative skincare. Since its foundation in 2019, the company has built its portfolio — including RG60®, Proluma™, Citrus Bottle™ and the Exoluma™ series — on three principles: scientifically verifiable formulations, regulatory compliance in every market entered, and continuous engagement with the international clinical and academic community. Genèse Labs partners with dermatologists, aesthetic physicians, and distributors worldwide to advance the standard of modern aesthetic medicine. For more information: www.geneselabs.net.